Caption Management’s Janux Therapeutics JANX Stock Holding History

Caption Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,488	Closed	-$21.6K	–	1863
2026 Q1	$20.7K	Sell	1,488 -271,012	-99%	-$3.72M	﹤0.01%	1456
2025 Q4	$3.76M	Buy	272,500 +182,500	+203%	+$4.29M	0.03%	598
2025 Q3	$2.2M	Sell	90,000 -367,012	-80%	-$8.94M	0.02%	815
2025 Q2	$10.6M	Buy	457,012 +412,569	+928%	+$10.9M	0.12%	195
2025 Q1	$1.2M	Sell	44,443 -4,089	-8%	-$154K	0.01%	855
2024 Q4	$2.6M	Buy	+48,532	New	+$2.57M	0.02%	608

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Caption Management's JANX Position: Q2 2026 in Review

Caption Management sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 1,488 shares — an estimated $21.6K sold.

Caption Management first reported a position in JANX in Q4 2024 and held it in 6 quarters. The position peaked at $10.6M in Q2 2025. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Caption Management reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
Caption Management sold 1,488 Janux Therapeutics shares in Q2 2026, an estimated $21.6K.
Caption Management first reported a position in Janux Therapeutics in Q4 2024 and held it in 6 quarters.
Caption Management's Janux Therapeutics position peaked at $10.6M in Q2 2025.
197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.